NasdaqCM:NEOHealthcare
A Look At NeoGenomics (NEO) Valuation After The Launch Of PanTracer Pro In Precision Oncology
NeoGenomics (NEO) has launched PanTracer Pro, a new molecular testing solution that combines comprehensive genomic profiling with diagnosis-directed assays for advanced solid tumors. The solution is designed to streamline biomarker assessment and support quicker, informed treatment decisions.
See our latest analysis for NeoGenomics.
The launch of PanTracer Pro comes as NeoGenomics' share price sits at US$11.38. This follows a 30 day share price return decline of 13.92%, contrasting with a...